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dysfunction and oxidative stress in
acetaminophen-induced hepato-renal injury
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Background: Acetaminophen (APAP)-induced toxicity is a predominant cause of acute hepatic and renal failure.
In both humans and rodents toxicity begins with a reactive metabolite that binds to proteins. This leads to
mitochondrial dysfunction and nuclear DNA fragmentation resulting in necrotic cell death. Pleurotus ostreatus
(an edible oyster mushroom) is well recognized as a flavourful food, as well as a medicinal supplement. In
the present study, we evaluated the role of Pleurotus ostreatus in the protection against APAP-induced
hepato-renal toxicity. We also explored the mechanism by which Pleurotus ostreatus exerts its effects.
Methods: Ninety adult male Swiss albino mice were divided into three groups (30 mice/group). Mice were offered
normal diet (control and APAP groups), or diet supplemented with 10% Pleurotus ostreatus (APAP + Pleurotus
ostreatus) for 10 days. Mice were either treated with vehicle (control group, single intra-peritoneal injection.),
or APAP (APAP and APAP + Pleurotus ostreatus groups, single intra-peritoneal injection, 500 mg/kg), 24 hours
after the last meal.
Results: APAP increased serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST)
glutamate dehydrogenase (GDH), creatinine, blood urea nitrogen (BUN), urinary kidney injury molecule-1 (KIM-1),
and hepatic and renal malondialdehyde (MDA) content. APAP decreased hepatic and renal glutathione (GSH) content,
as well as glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities. Supplementation with Pleurotus
ostreatus significantly reduced APAP-induced elevated levels of ALT, AST, GDH, creatinine, BUN, KIM-1and MDA,
while GSH level, and GSH-Px and SOD activities were significantly increased. Our findings were further validated by
histopathology; treatment with Pleurotus ostreatus significantly decreased APAP-induced cell necrosis in liver and
kidney tissues.
Conclusions: We report here that the antioxidant effect of Pleurotus ostreatus opposes mitochondrial
dysfunction and oxidative stress accompanying APAP over-dose, with subsequent clinically beneficial effects
on liver and kidney tissues.
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Acetaminophen (N- acetyl-p-aminophenol, APAP) is a
widely prescribed non-narcotic analgesic and antipyretic
drug. APAP is commonly sold in the clinic as well as
numerous over-the-counter preparations either as a single
compound or in combination with other drugs [1-3].
APAP is metabolized by cytochrome P450 (CYP) to form
the highly reactive species, N-acetyl-p-benzoquinone imine
(NAPQI), which under normal conditions is readily de-
toxified by conjugation with glutathione (GSH). However,
an overdose of APAP can lead to severe liver and/or kid-
ney injury in humans and in experimental animals [4,5].
Most importantly, in the presence of hepatic, renal or car-
diopulmonary insufficiency, even therapeutic doses of
APAP may cause hepato-renal damage [6,7]. High doses
of APAP saturate the detoxification pathways [8]; deple-
tion of GSH leaves NAPQI free to bind to possibly critical
cellular proteins and cause cell necrosis. Therefore, APAP
toxicity is determined by the amount of NAPQI produced
and the insufficient availability of GSH for APAP detoxifi-
cation [9-11].
Reactive oxygen species (ROS) are fundamentally cor-
related to oxidative stress. ROS have been implicated in
a number of disease processes, including hepatic injury,
renal injury, cardiac diseases, neurodegenerative diseases,
diabetes, pulmonary diseases as well as cancer [12-20].
Maintaining the balance between the production of ROS
and the availability of antioxidant enzymes, such as super-
oxide dismutase (SOD), catalase (CAT), and glutathione
peroxidase (GPx), is consequently critical. This could be an
important mechanism for preventing the oxidative stress-
induced tissue damage. ROS-antioxidants balance has been
suggested to have an important role in the development of
APAP toxicity [5]. Lipid peroxidation, mediated by ROS, is
believed to be an important cause of cell membranes dam-
age. The role of ROS in mediating the microvascular dis-
turbances that precede tissue damage induced by various
chemicals has gained much attention. It has been shown
that, during APAP intoxication in the mouse, toxic ROS
are generated and actively participate in the pathophysio-
logical process leading to hepatocyte necrosis [4].
Scientific and clinical interests have risen towards the
use of mushrooms with potential therapeutic effects. Ed-
ible mushrooms are a valuable source of biologically active
compounds. The medicinal potential of edible mushrooms
arises from the fact that they are natural, less expensive
and have minimal side effects. Mushrooms demonstrate
their efficiency against numerous diseases and metabolic
disturbances. These therapeutic effects seem to be under-
lined by multiple complex cellular and molecular actions
[21]. Pleurotus ostreatus (an oyster mushroom) is one of
the widely cultivated edible mushrooms. Pleurotus ostrea-
tus demonstrated antioxidative, hypocholesterolemic, and
antiatherogenic activities [22]. Antitumor properties [23],as well as the ability to enhance the immune system have
also been reported [24].
In the present study, we aimed to evaluate the protective
effects of Pleurotus ostreatus on APAP-induced hepato-
renal toxicity in mice, with emphasis on mitochondrial
dysfunction trying to elucidate the mechanism(s) by which
Pleurotus ostreatus may execute its protective effect.
Methods
Animals
Ninety male Swiss albino mice, 10–14 weeks old weighing
approximately 20–25 g, were used in the present study.
Mice were maintained under controlled temperature, hu-
midity, and 12 hour light/dark cycles. The animals were
fed standard rodent chow and allowed free access to water
ad libitum, and were kept for 10 days prior to any pro-
cedure to allow proper acclimatization. Animal care and
use was approved by the Ethics Committee of Faculty of
Medicine-Menoufia University-Egypt. The experiments
were carried in accordance with the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication no. 85–23,
revised in 1996).
After acclimatization, mice were divided randomly into
the following groups (30 mice/group): (1) control group,
(2) APAP group, and (3) APAP + Pleurotus ostreatus group.
Mice in the control and APAP groups were fed normal
rodent diet; while those in the APAP + Pleurotus ostreatus
group were fed normal rodent diet supplemented with
10% Pleurotus ostreatus for 10 consecutive days. Mice
were fasted for 12 hours before treatment with APAP or
vehicle as indicated. Acute liver injury was induced in
APAP and APAP + Pleurotus ostreatus groups by a single
intra-peritoneal (i.p) injection of 500 mg/kg APAP (Sigma-
Aldrich Co., Mo, USA) dissolved in warm phosphate-
buffered saline (PBS, pH 7.4). Control mice were injected
with equal volumes of the vehicle.
Five mice from each group were scarified either just
before (0), or after (1, 2 and 8) hours following APAP or
vehicle treatment. The aim of the separate experiment
was to validate the anti-oxidant properties of Pleurotus
ostreatus.
Collection of oyster mushroom
Mature fruiting bodies of Pleurotus ostreatus were kind
gift from Dr Mohamed F Salem (Genetic Engineering and
Biotechnology Research Institute, Sadat City University,
Egypt). The fruiting bodies were dried in sunlight and
crushed into powder. The powder was mixed with the
basal diet.
Characterization of oyster mushroom dried powder
Protein, fat and ash contents were determined using
standard analytical methods [25]. Total dietary fiber
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ary fiber and was determined using enzymatic method
[26]. Analytical determinations were conducted in three
independent replications and the results are presented in
grams per 100 g dry powder.
The amino acid composition was identified as described
previously [27]. High performance liquid chromatography
(HPLC) analysis was carried out in an Agilent 1220 Infinity
system (Santa Clara, CA, USA). The amino acid compos-
ition was expressed as percentage of protein.
Blood and tissue samples collection
All mice were scarified 24 hours after APAP injection.
Blood was drawn from each mouse via cardiac puncture.
The blood was allowed to coagulate for 30 minutes at
room temperature. Blood samples were then centrifuged
at 2000 rpm for 10 min to separate serum samples. Serum
samples were stored at −20°C. Serum samples were used
for the estimation alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), glutamate dehydrogenase
(GDH), creatinine and blood urea nitrogen (BUN).
The liver and kidneys were carefully dissected from the
fat and connective tissue. The tissues were rinsed several
times with cold saline and air dried on filter paper. Liver
and kidney specimens were used for the preparation of tis-
sue homogenates and tissue slides for Haematoxylin and
Eosin (Hx & E) stain.
Urine samples collection
Urine samples from the mice were collected on day 1 after
disease induction. 24-hour urine collection using meta-
bolic cages was carried out for all mice. All collected urine
samples were aliquoted and frozen away.
Preparation of tissue homogenates
Specimens from the liver and kidney were weighted
and homogenized separately with tissue homogenizer
(MPW120, MPWMedical Instruments, China). For estima-
tion of tissue glutathione (GSH), malondialdehyde (MDA)
levels and the activities of glutathione peroxidise (GSH-Px),
tissues were homogenized in phosphate buffer saline (PBS)
50 mM pH 7.4. For estimation of superoxide dismutase
(SOD) tissues were homogenized in potassium phosphate
buffer (PPB) 10 mM pH 7.4. The crude tissue homogenate
was centrifuged at 10,000 rpm, for 15 minutes in ice-cold
centrifuge, and the resultant supernatant was collected and
stored at −20°C.
Measurement of APAP protein adducts in liver tissue
homogenate
Measurement of APAP-cysteine (APAP-CYS) in liver tis-
sue homogenate was performed using high pressure liquid
chromatography with electrochemical detection (HPLC-
ECD) as described previously [28].Biochemical analysis
Serum levels of alanine aminotransferase (ALT), aspartate
aminotransferase (AST), creatinine and blood urea nitro-
gen (BUN) (ELITech, France), and glutamate dehydrogen-
ase (GDH) (QuantiChrom™, BioAssay Systems, USA) were
determined by routine kinetic and fixed rate colorimetric
methods on a Jenway Genova autoanalyser (UK) [29-31].
Urinary kidney injury molecule-1 (KIM-1) was measured
by a highly sensitive two-site enzyme linked immunoassay
(ELISA) (ALPCO Diagnostics, USA) [32,33].
Tissue levels of glutathione (GSH) and malondialdehyde
(MDA) (QuantiChrom™, BioAssay Systems, USA), gluta-
thione peroxidase (GSH-Px) and superoxide dismutase
(SOD) (EnzyChrom™, BioAssay Systems, USA), were de-
termined by colorimetric method [34-37].
Haematoxylin and Eosin (Hx & E) stain
Specimens from the liver and kidney were fixed in 10%
formol saline for 5–7 days. The specimens were washed
in tap water for 10 minutes and then dehydrated in
graded ethanol solutions (70%, 90% over night and 100%
ethanol solution for three changes one hour each). The
specimens were cleared in xylene (20–30 times). After
that, specimens were impregnated in soft paraffin wax at
55–60°C for two hours then in hard paraffin wax at room
temperature in moulds. Tissue blocks were cut into sec-
tion of 5 microns thickness by using rotator microtome.
Tissue sections were dipped in a warm water-bath, picked
up on clean slides, and placed on hot plate for two mi-
nutes. Finally, tissue sections were stained with haema-
toxylin and eosin stain for general architecture of the
studied tissues.
Statistical analysis
Results are expressed as mean ± standard error (SE).
Student t-test or repeated-measures Analysis of Variances
(ANOVA) were used for statistical analysis of the different
groups whichever appropriate, using Origin® software and
the probability of chance (p values). P values < 0.05 were
considered significant.
Results
Serum ALT increased significantly in the APAP-treated
group when compared to the control group (710.5 ± 25.8
vs 60.7 ± 8.2 IU, P < 0.05). Serum ALT levels were signifi-
cantly lower in the APAP + Pleurotus ostreatus group
than that in the APAP group (67.4 ± 8.2 IU, P < 0.05).
There was no statistically significant difference in serum
ALT between APAP + Pleurotus ostreatus and control
groups (P > 0.05) (Figure 1A).
Serum AST increased significantly in the APAP-treated
group when compared to the control group (645.7 ± 30.8
vs 72.4 ± 11.2 IU, P < 0.05). Serum AST levels were signifi-
cantly lower in the APAP + Pleurotus ostreatus group than
Figure 1 Pleurotus ostreatus protects against liver injury in APAP-overdose treated mice. (A) Serum ALT levels in control (white column),
APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (B) Serum AST levels in control (white column), APAP
treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (C) Serum GDH levels in control (white column), APAP
treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (D) Representative photomicrograph of Hx & E stained liver
sections from control, APAP treated and APAP + 10% Pleurotus ostreatus treated mice (×400). (Significant = p < 0.05, *significant when compared to
the control group, • significant when compared to the APAP treated group. Number of mice = 10/group).
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was no statistically significant difference in serum AST
between APAP + Pleurotus ostreatus and control groups
(P > 0.05) (Figure 1B).
Serum GDH increased significantly in the APAP-treated
group when compared to the control group (782.6 ± 36.5
vs 38.9 ± 6.3 IU, P < 0.05). Serum GDH levels were signifi-
cantly lower in the APAP + Pleurotus ostreatus group thanthat in the APAP group (41.7 ± 7.2 IU, P < 0.05). There
was no statistically significant difference in serum GDH
between APAP + Pleurotus ostreatus and control groups
(P > 0.05) (Figure 1C).
The appearance of liver tissues 24 hours after APAP in-
jection was confirmed by histopathological observation.
Centrilobular necrosis, sinusoidal congestion, lymphocytes
infiltration and Kupffer cells around the central vein, loss
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served after administration of acetaminophen. However,
mice treated with 10% Pleurotus ostreatus preserved nor-
mal hepatic architecture with minimal changes (Figure 1D).
Serum creatinine increased significantly in the APAP-
treated group when compared to the control group (1.26 ±
0.25 vs 0.31 ± 0.08 IU, P < 0.05). Serum creatinine levelsFigure 2 Pleurotus ostreatus protects against kidney injury in APAP-o
column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus trea
APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey
treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey colum
sections from control, APAP treated and APAP + 10% Pleurotus ostreatus treate
compared to the control group, • significant when compared to the APAP treatwere significantly lower in the APAP + Pleurotus ostreatus
group than that in the APAP group (0.34 ± 0.09 IU, P <
0.05). There was no statistically significant difference in
serum creatinine between APAP + Pleurotus ostreatus and
control groups (P > 0.05) (Figure 2A).
Serum BUN increased significantly in the APAP-treated
group when compared to the control group (98.4 ± 6.7 vsverdose treated mice. (A) Serum creatinine levels in control (white
ted (grey column) groups. (B) Serum BUN levels in control (white column),
column) groups. (C) Urinary KIM-1 levels in control (white column), APAP
n) groups. (D) Representative photomicrograph of Hx & E stained kidney
d mice (×400). (Significant = p < 0.05, *significant when
ed group. Number of mice = 10/group).
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cantly lower in the APAP + Pleurotus ostreatus group than
that in the APAP group (51.7 ± 9.2 IU, P < 0.05). There
was no statistically significant difference in serum BUN
between APAP + Pleurotus ostreatus and control groups
(P > 0.05) (Figure 2B).
Urinary KIM-1 increased significantly in the APAP-
treated group when compared to the control group (5.91 ±
0.76 vs 0.78 ± 0.11 ng/mg creatinine, P < 0.05). Urinary
KIM-1 levels were significantly lower in the APAP +
Pleurotus ostreatus group than that in the APAP group
(0.81 ± 0.18 ηg/mg creatinine, P < 0.05). There was no sta-
tistically significant difference in Urinary KIM-1 between
APAP + Pleurotus ostreatus and control groups (P > 0.05)
(Figure 2C).
Histopathological appearance of kidney tissues 24 hours
after APAP injection showed focal area of coagulative ne-
crosis and haemorrhage. Necrotic areas demonstrated
ghosts of renal tubules, casts and lymphocytic infiltrates.Figure 3 Anti-oxidant properties of Pleurotus ostreatus. (A) Liver and
column) and APAP + 10% Pleurotus ostreatus treated (grey column) gro
treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey colu
APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (gre
column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus tr
compared to the control group, • significant when compared to the APAP treThe necrotic areas were sharply separated from the adja-
cent normal renal tissue. However, no such changes were
evident in the kidneys of mice treated with 10% Pleurotus
ostreatus (Figure 2D).
Hepatic GSH was significantly lower in the APAP group
when compared to the control group (2.9 ± 0.32 vs 10.1 ±
1.6 μM/mg protein, P < 0.05). Hepatic GSH in APAP +
Pleurotus ostreatus group was significantly higher than in
the APAP group (9.16 ± 0.49 μM/mg protein, P < 0.05).
There was no statistically significant difference in hepatic
GSH between APAP + Pleurotus ostreatus and control
groups (P > 0.05). Renal GSH was significantly lower in
the APAP group compared to the control group (3.3 ±
0.64 vs 6.1 ± 1.2 μM/mg protein, P < 0.05). Renal GSH in
APAP + Pleurotus ostreatus group was significantly higher
than in the APAP group (5.9 ± 1.1 μM/mg protein, P <
0.05). There was no statistically significant difference in
renal GSH between APAP + Pleurotus ostreatus and con-
trol groups (P > 0.05) (Figure 3A).kidney GSH levels in control (white column), APAP treated (black
ups. (B) Liver and kidney MDA levels in control (white column), APAP
mn) groups. (C) Liver and kidney GSH-Px levels in control (white column),
y column) groups. (D) Liver and kidney SOD levels in control (white
eated (grey column) groups. (Significant = p < 0.05, *significant when
ated group. Number of mice = 10/group).
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group when compared to the control group (3.86 ± 0.61
vs 0.97 ± 0.12 μM/mg protein, P < 0.05). Hepatic MDA in
APAP + Pleurotus ostreatus group was significantly lower
than in the APAP group (0.99 ± 0.23 μM/mg protein, P <
0.05). There was no statistically significant difference in
hepatic MDA between APAP + Pleurotus ostreatus and
control groups (P > 0.05). Renal MDA was significantly el-
evated in the APAP group when compared to the control
group (3.45 ± 0.65 vs 0.83 ± 0.21 μM/mg protein, P < 0.05).
Renal MDA in APAP + Pleurotus ostreatus group was
significantly lower than in the APAP group (0.91 ±
0.13 μM/mg protein, P < 0.05). There was no statistically
significant difference in renal MDA between APAP +
Pleurotus ostreatus and control groups (P > 0.05) (Figure 3B).
Hepatic GSH-Px activity was significantly lower in the
APAP group when compared to the control group (0.29 ±
0.08 vs 0.61 ± 0.1 U/mg protein, P < 0.05). Hepatic GSH-
Px activity in APAP + Pleurotus ostreatus group were sig-
nificantly higher than in the APAP group (0.60 ± 0.2 U/mg
protein, P < 0.05). There was no statistically significant
difference in hepatic GSH-Px activity between APAP +
Pleurotus ostreatus and control groups (P > 0.05). Renal
GSH-Px activity was significantly lower in the APAP
group when compared to the control group (0.35 ± 0.06 vs
0.56 ± 0.02 U/mg protein, P < 0.05). Renal GSH-Px activity
in APAP + Pleurotus ostreatus group was significantly
higher than in the APAP group (0.54 ± 0.23 U/mg protein,
P < 0.05). There was no statistically significant differ-
ence in renal GSH-Px activity between APAP + Pleurotus
ostreatus and control groups (P > 0.05) (Figure 3C).
Hepatic SOD activity was significantly lower in the
APAP group when compared to the control group (16.4 ±
1.3 vs 41.3 ± 3.5 U/mg protein, P < 0.05). Hepatic SOD
activity in APAP + Pleurotus ostreatus group was signifi-
cantly higher than in the APAP group (37.6 ± 4.5 U/mg
protein, P < 0.05). There was no statistically significant dif-
ference in hepatic SOD activity between APAP + Pleurotus
ostreatus and control groups (P > 0.05). Renal SOD activ-
ity was significantly lower in the APAP group when com-
pared to the control group (8.4 ± 1.6 vs 21.3 ± 2.4 U/mg
protein, P < 0.05). Renal SOD activity in APAP + Pleurotus
ostreatus group was significantly higher than in the APAP
group (19.3 ± 3.6 U/mg protein, P < 0.05). There was
no statistically significant difference in renal SOD ac-
tivity between APAP + Pleurotus ostreatus and control
groups (P > 0.05) (Figure 3D).
In a separate experiment, 5 mice from each group were
scarified just before (0), or after 1, 2 and 8 hours following
APAP or vehicle treatment. APAP-CYS adducts and GSH
depletion was measured in liver tissue homogenate, while
hepatocyte injury was monitored by measuring serum
ALT (Figure 4). Pre-treatment with Pleurotus ostreatus
did not alter the metabolic activation of APAP as indicatedby the insignificant change in APAP-CYS adducts forma-
tion at 1, 2 and 8 (Figure 4A). Simultaneously, Pleurotus
ostreatus treatment restored APAP-induced GSH deple-
tion 8 hours after APAP treatment (Figure 4B). Hepato-
cyte injury was only evident after 8 hours following APAP
treatment as indicated by serum ALT level (Figure 4C).
Discussion
Pleurotus ostreatus or its constituents have been re-
ported to possess potent antioxidant, antihypercholester-
olemic, immunomodulatory and anticancer properties
[22-24]. However, potential hepatoprotective or nephro-
protective effects and the possible involvement of anti-
oxidant properties as the underlying mechanism have
not been reported. Up to our knowledge, we report here
for the first time that Pleurotus ostreatus has hepatopro-
tective and nephroprotective properties, as evidenced by
the significant inhibition of APAP-induced changes in liver
and kidney histopathology, biochemical parameters, anti-
oxidant enzymatic activities, and lipid peroxidation prod-
ucts. We further show that the antioxidant properties may,
at least in part, elucidate the underlying mechanism.
In the present study we demonstrated that the adminis-
tration of high doses of paracetamol significantly in-
creased serum levels of acute liver damage indicators. The
serum levels of GDH, ALT and AST were significantly ele-
vated following paracetamol administration. GDH is a key
enzyme in amino acid oxidation and a potential biomarker
of drug-induced hepatic toxicity [38]. In common with
GDH, serum ALT is considered to be a significant indica-
tor of acute liver damage [39]. These enzymes are present
in the hepatocyte cytoplasm; therefore, damaged hepato-
cytes release their contents including GDH, ALT and AST
into the extracellular space. The released enzymes ultim-
ately enter the circulation and thereby increase the serum
levels. Treatment with Pleurotus ostreatus protected the
liver against paracetamol induced hepato-cellular injury.
This was evident by the decrease in serum GDH, ALT
and AST activities. The observed hepato-protective effect
might be a consequence of the amelioration of the under-
lying mechanisms by which APAP cause cellular damage,
with subsequent suppression of the leakage of these en-
zymes into the blood.
Our results also revealed significant renal impairment in
animals treated with paracetamol, demonstrated by the in-
crease in serum creatinine and BUN, and urinary KIM-1
levels. High doses of paracetamol have been shown to
cause acute and chronic renal failure in experimental ani-
mals. The mechanism involved included deficits in the
antioxidant defense mechanisms, and lipid peroxidation in
renal tissue [40]. Recent work has demonstrated the
potential role of KIM-1 as a sensitive and specific tissue
biomarker. KIM-1 is thought to improve the early detec-
tion of acute kidney injury following the exposure to
Figure 4 (See legend on next page.)
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Figure 4 Effects of Pleurotus ostreatus on APAP-CYS adduct formation and GSH depletion. (A) APAP-CYS adduct level in liver tissue
homogenate at 0, 1, 2 and 8 hours post APAP or saline pre-treatment in control (white column), APAP treated (black column) and APAP
+ 10% Pleurotus ostreatus treated (grey column) groups. (B) GSH level in liver tissue homogenate at 0, 1, 2 and 8 hours post APAP or saline
pre-treatment in control (white column), APAP treated (black column) and APAP + 10% Pleurotus ostreatus treated (grey column) groups. (C) Serum
ALT levels at 0, 1, 2 and 8 hours post APAP or saline pre-treatment in control (white column), APAP treated (black column) and APAP + 10% Pleurotus
ostreatus treated (grey column) groups. (Significant = p < 0.05, *significant when compared to the corresponding control group at the same time
point, • significant when compared to the corresponding APAP treated group at the same time point. Number of mice = 5/group).
Table 1 The macro-components (g/100 g dried extract)
and amino acids constituents (mg/g weight) of dried
Pleurotus ostreatus
Macro-components g/100 g dried extract
Water 5.23 ± 0.29
Protein 28.15 ± 0.46
Fat 0.38 ± 0.02
Total Dietary Fiber 23.40 ± 0.05
Carbohydrates 49.30 ± 0.13
Ash 4.90 ± 0.05
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showed evidence for potential nephro-protective proper-
ties of Pleurotus ostreatus. Administration of Pleurotus
ostreatus significantly reduced the increased serum cre-
atinine and urinary KIM-1 to normal levels. Our findings,
thus far, showed that Pleurotus ostreatus can oppose the
injurious effects caused by high doses of APAP in the kid-
neys as well as the liver.
Histopathology findings confirmed the protective ef-
fect of Pleurotus ostreatus against APAP-induced liver
and kidney damage. The histological appearance of
the liver and kidney in the control group appeared
normal. APAP treatment caused centrilobular necrosis,
fatty changes (steatosis) and scattered lymphocytes infil-
trate in hepatic parenchyma. Administration of APAP pro-
voked renal proximal tubular coagulative necrosis and
hemorrhage. It has been reported previously that APAP
over-dose causes ultrastructural changes in the liver and
kidneys [42,43]. Following Pleurotus ostreatus administra-
tion, as shown in Figures 1D and 2D, the majority of liver
and kidney tissues preserved their normal architecture
with minimal inflammatory changes. Based on our find-
ings, it is clear that of Pleurotus ostreatus can avert APAP-
dependent cellular damage, thus preserving both the
morphology and the function of liver and the kidneys. We
were excited then to elucidate the underlying mechanisms.
Considerable progress has been made in animal models
toward understanding the mechanisms of APAP toxicity.
The majority of the therapeutic dose (>90%) of APAP is
glucuronidated or sulfated and then excreted. A small per-
centage is metabolized by cytochrome P450 enzymes
(CYP), in both the liver and the kidney, to the reactive
intermediate N-acetyl-p-benzoquinone imine (NAPQI),
which is readily detoxified by conjugation with glutathione
(GSH) [44,45]. From rodent studies, we know that higher
doses of paracetamol saturate the glucuronidation and sul-
fation pathways, resulting in formation of excess NAPQI.
The additional reactive metabolite depletes liver GSH and
binds to proteins [46,47]. Toxic doses of APAP could
cause changes in the morphology and function of liver
mitochondria [48,49]. It was suggested that NAPQI bind-
ing to mitochondrial proteins leads to mitochondrial
oxidative stress. It is now known that this causes the
mitochondrial membrane permeability transition (MPT)
pore opening, matrix swelling, and outer membrane lysisin rodent models [42,50-52]. The permeabilization and
lysis result in the release of apoptosis-inducing factor
(AIF) and endonuclease G (EndoG) from mitochondria.
These endonucleases translocate to nuclei and cause nu-
clear DNA fragmentation. Proapoptotic proteins, includ-
ing cytochrome c and Smac/DIABLO, are also released.
The end result is centrilobular hepatocyte necrosis and
liver failure [8].
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role in cellular toxicity, as well as the pathophysiology
several diseases. When the generation of ROS overcomes
the antioxidant capacity, the free radicals can then inter-
act with endogenous macromolecules and alter the cel-
lular functions and even integrity. In the present study,
high doses of APAP caused a significant rise in MDA
and reduction in GSH levels in mice hepatic and renal
tissues, with simultaneous inhibition of the antioxidant
enzymes GSH-Px and SOD. Lipid peroxidation is a well-
established mechanism of cellular injury. Lipid hydroper-
oxides are byproducts of lipid peroxidation, and increased
levels of lipid peroxidation products are associated with a
variety of chemical-induced toxicities including APAP.
Lipid hydroperoxides are known to cause cellular injury by
inactivation of membrane enzymes and receptors, depoly-
merizaton of polysaccharide, as well as protein cross link-
ing and fragmentation [8]. A rapid depletion of GSH and
lipid peroxidation has been also reported in both liver
[53] and kidney [40] of animals treated with high doses
of paracetamol. Paracetamol toxicity in the liver is
mainly mediated by the covalent binding of NAPQI, the
reactive metabolite of paracetamol, to sulfhydryl groups
of GSH, and other cellular proteins and their subse-
quent oxidation. Overproduction of free radicals in the
paracetamol treated mice may have triggered lipid per-
oxidation, and consequently increased MDA contents.
This may also explain the diminished GSH contents; as
to combat the increased formation of free radicals GSH
stores might have been depleted. Decrease in GSH
content can simultaneously decrease the activities of anti-
oxidant enzymes such as GSH-Px, SOD and glutathione-S-
transferase (GST) [4]. Administration of Pleurotus ostreatus
significantly ameliorated the paracetamol-induced increase
in MDA level and depletion of GSH contents toward nor-
mal values, with restoration of GSH-Px and SOD normal
activities.
We validated the anti-oxidant properties of Pleurotus
ostreatus by measuring APAP protein adducts formation
and GSH levels in liver tissue homogenate. It is well
known that APAP metabolic activation results in the for-
mation of the reactive metabolite NAPQI, which reacts
with GSH and with cysteine (CYS) residues on proteins
[9]. Therefore, early GSH depletion kinetics (0–1 hour)
may provide a logical proof on whether treatment with
Pleurotus ostreatus prevents the metabolic activation of
APAP or not. As illustrated by the kinetics (Figure 4),
there was no significant difference in GSH depletion
between mice treated with APAP and vehicle or APAP
and Pleurotus ostreatus 60 min after APAP overdose
suggesting that Pleurotus ostreatus had no impact on
the metabolic activation of APAP. However, later kin-
etics (8 hours) demonstrated that Pleurotus ostreatus
resulted in substantial reduction in overall proteinadduct formation suggesting that an anti-oxidant incident
opposed APAP-induced oxidative stress. Characterization
of the mushroom extract (Table 1) revealed the presence
of both essential and non-essential amino acids as tabu-
lated (Table 1). Tyrosine, histidine, lysine and tryptophan,
are generally accepted as antioxidants. Methionineis is a
sulfur-containing antioxidant amino acid with well estab-
lished clinically relevant anti-oxidant properties [54]. The
presence of all these amino acids provides Pleurotus
ostreatus with substantially a potent antioxidant capacity.
Conclusion
In summary, mitochondria are prominent targets for the
toxicity of several molecules, including APAP. Mitochon-
drial dysfunction results in the impairment of energy me-
tabolism and an intracellular oxidative stress with excessive
formation of ROS. The antioxidant properties of Pleurotus
ostreatus opposed mitochondrial dysfunction, and pro-
tected the liver and kidney tissues against APAP-induced
acute inflammation.
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